NEW YORK, April 18, 2017 /PRNewswire/ -- Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Allergan, Inc. related to Argentum's generic version of RESTASIS® (0.05% cyclosporine ophthalmic emulsion).
The agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the patents covering RESTASIS®. The specific date on which Argentum may launch its generic product and other details concerning the settlement have not been disclosed.
RESTASIS® is a registered trademark of Allergan, Inc.
SOURCE Argentum Pharmaceuticals